The Src-family protein tyrosine kinases (SFKs) are known to play key roles in initiating signal transduction by the B-cell antigen receptor (BCR). In addition, numerous studies have shown that this family of molecules also contributes to signaling by BCR surrogates during B-lymphocyte lineage development and maturation. Paradoxically, ablation of SFKs not only results in obvious defects in B-cell development but also in the onset of autoimmunity. Thus SFKs, most notably Lyn, play both activating and inhibitory roles in B-cell function. Confounding analyses of SFK function in B cells is the varied coexpression of family members that mediate redundant as well as unique functions. In this review, we will focus mainly on the role of Lyn in mediating positive and negative roles in B-cell activation and how these affect immune signaling and disease progression.
Structure/activation
The Src-family protein tyrosine kinase (SFKs) are approximately 60 kDa proteins that share considerable homology in their domain structure. Each contains six functional domains (Tatosyan and Mizenina, 2000) : an N-terminal SH4 domain followed by a 'unique' domain, an SH3, SH2, a catalytic (or SH1) domain, followed by a C-terminal region. The N-terminal SH4 domain is known to play key roles in the localization of SFKs to the cell membrane due in part to acylation sites. All Bcell expressed SFKs contain acylation sites for both myristate and palmitate except Blk, which is only myristoylated. Removal of Gly2 (myristoylation) or Cys3 (palmitoylation) residues prevents membrane localization of SFKs and subsequent activation by receptor binding stimuli (Resh, 1999) . The SH3 and SH2 domains play key roles in regulating the catalytic potential of activated SFKs. The SH3 domain binds proline-rich domains (PXXP) that promotes the association of SFKs with intracellular substrates. The SH2 domain also promotes binding to intracellular substrates (Tatosyan and Mizenina, 2000) , by a binding preference for certain phosphotyrosine containing motifs (particularly YEEI) (Tatosyan and Mizenina, 2000) , which include the ITAM motifs of Ig-a/b . X-ray and crystallographic data suggest that intramolecular associations between SH3 and SH2 domains regulate SFK activation (Xu et al., 1999) . In the resting (inactive) state, binding of the C-terminal phospho-Y527 to the SH2 domain helps keep the SFK molecules in a 'closed' confirmation that attenuates SFK activity. Current literature suggests that Csk, in association with Cbp/PAG at the plasma membrane (Brdicka et al., 2000) , phosphorylates Y527 promoting its inactivity (Nada et al., 1991) . Activation of SFKs therefore requires the dephosphorylation of this tyrosine residue that is believed, in part, to be carried out by the protein tyrosine phosphatase CD45. This dephosphorylation event results in the unfolding of SFKs exposing Y416, which requires phosphorylation for full SFK activity (Cahir McFarland et al., 1993) .
Role of SFKs in tonic and aggregation-dependent B-cell antigen receptor (BCR) signaling
Aggregation of the BCR by antigen is known to induce the rapid yet coordinated activation of various signaling cascades. Great progress has been made in the last decade in understanding the relationship between resting-and receptor-mediated association of SFKs (Lyn, Fyn, Blk, Hck, Fgr and Lck; Saijo et al., 2003) to the BCR complex. Central to this process is the expression of dual-tyrosine containing ITAM motifs in the cytoplasmic tails of Ig-a and Ig-b (Cambier, 1995) . Dual ITAM phosphorylation occurs following aggregation of antigen receptors by antigen and is secondary to the activation of SFKs such as Lyn. However, while Lyn is not absolutely required for the initiation of BCR signaling, it appears to be the primary SFK utilized in this process. We will therefore focus the majority of this review article on the activation and biological role of Lyn in B-lymphocytes.
The receptor proximal activation of Lyn following BCR aggregation places this molecule as a key regulator of many downstream signaling events with varied biological responses including B-cell maturation, apoptosis, proliferation and tolerance. The coupling of BCR and Lyn activation to these distinct outcomes is known to depend on the strength of BCR signal, the developmental stage of the B cell and coreceptor function, for example, CD19/CD22. For example, in immature B cells recognizing antigen, a strong BCR signal is known to result in Lyn-dependent activation of Syk and the activation of proapoptotic pathways. However, a weaker BCR signal couples Lyn through a Syk-independent pathway that is thought to induce a state of anergy (reviewed in Hsueh and Scheuermann, 2000) . Lyn activation is also known to promote apoptosis in mature B cells in a Fas-dependent manner (Wang et al., 1996) , highlighting a role for Lyn in BCRindependent signaling pathways. Indeed, MHC class II aggregation on activated B cells is also known to signal via Lyn (Lang et al., 2001) .
While Lyn is known to phosphorylate directly both Syk and Btk (key molecules required for PLCg2 phosphorylation and intracellular free calcium mobilization) following BCR-aggregation (reviewed in Kurosaki, 1999) , studies using Lyn-deficient B cells have shown that these cells are, surprisingly, hyper-responsive to BCR stimulation (Chan et al., 1997) . These studies can now be explained by the unique role for Lyn in the phosphorylation of both CD19 and CD22 (see below), which positively and negatively regulate BCR signaling, respectively. Therefore, while Lyn is a key molecule in the initiation of signaling pathways such as the MAP kinases and calcium mobilization, both of which play key roles in B-cell activation and proliferation, it perhaps plays a more important role in modulating signal strength by regulating coreceptors such as CD19 and CD22.
In resting B cells, Lyn associates weakly with the BCR by virtue of an interaction between the N-terminal domain of Lyn and the nonphosphorylated ITAM domain (preferentially Ig-a) (Yamanashi et al., 1991; Clark et al., 1992 Clark et al., , 1994 Pleiman et al., 1994) . This weak interaction is further stabilized by Lyn binding to the plasma membrane by its SH4 domain (Resh, 1993 (Resh, , 1994 .
Interestingly, BCR-associated Lyn in resting B cells is maintained in a continuously changing balance between 'inactive' and 'partially active' states due to the opposing effects of Csk (phosphorylation) and CD45 (dephosphorylation) on the C-terminal tyrosyl residue Y508 (analogous to Y527 of Src). Findings suggest that the partially active conformation is the predominant state in resting B cells, and this kinase 'primes' B cells for activation following antigen receptor aggregation. Receptor aggregation probably functions to colocalize and concentrate enzyme/substrate molecules to help drive and amplify signal transduction events. While phosphorylation of dual ITAM tyrosines by SFKs is thought by many to be the 'initiation' phase of BCR signaling, an earlier phase that promotes full SFK activation must occur first. Interestingly, studies have shown that single ITAM tyrosine phosphorylation is sufficient to drive Lyn recruitment and activation, while dual ITAM phosphorylation is essential for binding and activation of Syk (Johnson et al., 1995; Pao et al., 1998) . These same studies also highlighted the asymmetrical nature of ITAM tyrosine phosphorylation, with single ITAM tyrosine phosphorylation accounting for approximately 80% of ITAM motifs following BCR aggregation.
It is clear from studies that the initiation of BCRmediated (and TCR-mediated; Lee et al., 2002) signaling events can occur outside of glycolipid-rich microdomains (Sproul et al., 2000) . In addition, in B cells treated with agents to deplete membrane cholesterol, BCR aggregation still leads to tyrosine phosphorylation events and [Ca 2 þ ] i responses are actually enhanced (Awasthi-Kalia et al., 2001) . Thus, it is interesting to speculate that glycolipidrich microdomains, although postulated to initiate signaling events, may function primarily in amplification. However, they may also be inhibitory in nature and contribute to signal termination (Lee et al., 2003) .
Tonic BCR signaling is essential for both the development and survival of B cells (Fuentes-Panana et al., 2004) , but may also contribute to the ability of antigen receptor aggregation to induce intracellular signaling events. Tonic signaling is regulated by a balance of both positive (kinase) and negative (phosphatase) signaling events, which occur in a ligandindependent manner. Treatment of resting splenic B cells with phosphatase inhibitors such as sodium fluoride and pervanadate induce tyrosine phosphorylation of Ig-a/b (Campbell et al., 1995; Wienands et al., 1996) . Interestingly, global phosphorylation events associated with pervandate stimulation require expression of Ig-a/b (Pracht et al., 2002) . It would therefore appear that resting splenic B cells have continuous basal tyrosine kinase and phosphatase activities that target Ig-a/b oppose each other reaching an equilibrium that favors low levels of kinase activity and tonic signaling.
Numerous studies have shown that loss of CD45 results in hyperphosphorylation of Lyn (Pao and Cambier, 1997) (on both the major tyrosine sites, Y397 and Y508) and an increase in its kinase activity (Yanagi et al., 1996; Katagiri et al., 1999) . During BCR aggregation, initial Lyn activation probably happens due to the concentration of BCR-associated Lyn and may be enhanced or inhibited by a transient loss of CD45 as the aggregated BCRs form larger glycolipidrich microdomains. The disassociation of SHP-1 from the BCR complex (Pani et al., 1995) may also help facilitate further amplification. Once these 'primed' Lyn molecules are allowed to associate closely with each other, the rate of transphosphorylation of Y397 (the Y416 homologue of Src) by other Lyn molecules would presumably exceed any dephosphorylation by CD45 that is reported to accumulate in these BCR/Lyn-rich glycolipid microdomains moments after BCR aggregation (Gupta and DeFranco, 2003; Shrivastava et al., 2004) . The resulting activation of Lyn could then serve to phosphorylate tyrosine containing ITAM motifs on both Ig-a/b, generating high-affinity docking sites for both Lyn and Syk via SH2 domain interactions. This is postulated to change the orientation of Lyn and Ig-a/b, promoting Lyn activity or its ability to interact with substrate molecules ) (see Figure 1) .
The activation of Lyn proximal to the BCR has also been shown to further amplify BCR signal strength by the phosphorylation of tyrosine residues on the cytoplasmic tail of CD19 (Roifman and Ke, 1993) and the recruitment of molecules such as Vav and PI(3)K (Tuveson et al., 1993; Lankester et al., 1994; Weng et al., 1994; Buhl et al., 1997; Sato et al., 1997; O'Rourke et al., 1998) . Findings suggest that Lyn and CD19 are involved in a 'progressive amplification loop' in which Lyn is essential for CD19 phosphorylation and CD19 then acts as a site for further Lyn recruitment and activation (Fujimoto et al., 1999b (Fujimoto et al., , 2000a (Fujimoto et al., , b, 2001 . Indeed, studies using CD19 À/À cells have shown that lack of CD19 leads to a reduction in tyrosine phosphorylation of multiple effector molecules following BCR aggregation (Buhl et al., 1997) including Lyn. In addition, in vitro kinase assays have shown that kinase activity of purified Lyn was significantly increased when coincubated with purified CD19 (Fujimoto et al., 1999b) . These results suggest that phosphorylated Lyn and phosphoryated Ig-a/b cytoplasmic tails (Johnson et al., 1995) , as well as CD19, function to amplify Lyn activity and that loss of this Lyn amplification may account for the hyporesponsiveness of the BCR in CD19 À/À B cells. Coengagement of CD19 upon BCR aggregation may also act to amplify signals by sequestering pools of active Lyn away from negative regulators such as CD22 ).
Role of SFKs as negative regulators of BCR signaling
Studies using cell lines and mice deficient in SFKs have shown that while these molecules are important for signal initiation, they also play an important role in activating signaling loops that are important for signal termination. In particular, Lyn is known to be a key component in the phosphorylation of inhibitory, ITIMcontaining coreceptors. Indeed, while Lyn plays a key role in signal initiation, B cells from Lyn À/À mice exhibit a hyperresponsive phenotype (Nishizumi et al., 1998) that may result from a lack of inhibitory receptor activation or inhibitory feedback loops.
The best studied inhibitory BCR coreceptors are FcgRIIB and CD22, which are both Lyn substrates (Nishizumi et al., 1998; Smith et al., 1998) . FcgRIIB, a low-affinity receptor for IgG constant regions is activated when B cells encounter immune complexes recognized by both BCR and FcgRIIB. CD22, a B-cellspecific transmembrane protein belonging to the Siglec family binds alpha2,6-linked sialic acid residues and is associated with membrane IgM. Studies suggest that upon BCR aggregation, Lyn sequestered from CD19 pools mediates CD22 phosphorylation (Fujimoto et al., 2000b) . It is thought that CD19 and CD22 oppose each other in the regulation of signal strength. Indeed, CD19 has been shown to be a direct substrate of SHP-1, a tyrosine phosphatase recruited by CD22 (Fujimoto et al., 1999a) . The recruitment of SHP-1 to CD22 has been shown to correlate directly with the phosphorylation state of two of its three ITIM motifs (Otipoby et al., 2001) . Interestingly, the phosphorylation state of ITIMcontaining receptors does not always correlate with their activity. Numerous studies have shown that loss of Lyn, while having a dramatic effect on FcgRIIB ITIM phosphorylation, only has a modest effect on the ability of FcgRIIB to downmodulate BCR-mediated signaling Lyn also inhibits BCR-mediated signaling events by phosphorylation and activation of Cbl that targets Syk for ubiquitination and degradation. Lyn also inhibits Syk activity by direct phosphorylation of inhibitory tyrosine residues in the linker region of Syk. Phosphorylation of Dok in a Lyn-dependent manner also promotes SHIP activity and subsequent hydrolysis of PI(3,4,5)P 3 . Lyndependent phosphorylation of FcgRIIB also promotes recruitment of SHP-1 and SHIP, which attenuate BCR-mediated signaling events (not shown in figure) events DeFranco et al., 1998) . The reason for this is unclear, but is probably due to the ability of FcgRIIB to recruit other signaling molecules in a SH2 domain-independent manner at a site distinct from the ITIM sequence. Indeed, studies have shown that FcgRIIB mutants with truncations that include the ITIM sequence still promote CD19 dephosphorylation and inhibit BCR signaling (Fong et al., 2000) . Other ITIM-containing receptors known to be directly regulated by Lyn include CD5 (Sen et al., 1999) , CD72 (Adachi et al., 1998) , PD-1 (Okazaki et al., 2001 ) and PIR-B (Maeda et al., 1999) . Lyn therefore plays a key role in the initiation of negative signaling events in B cells by regulating a wide range of receptors expressed on different B-lymphocyte subsets. Studies have also identified an apparent gene dosage effect when differentially expressing various amounts of Lyn, CD22 and SHP-1. Interestingly, these findings indicate that subtle changes in the expression of these proteins can be partially compensated by the modulation of surface IgM expression. However, if these defects result in decreases in the threshold of signaling too much, then B-cell hyperactivity occurs (Cornall et al., 1998) .
A recently discovered role for Lyn in the phosphorylation of an inhibitory tyrosine residue in the linker region of Syk (Hong et al., 2002) suggests that Lyn can also mediate negative signaling events by acting directly on downstream substrates without the use of inhibitory coreceptors such as CD22. Another example would be Lyn-mediated phosphorylation of Cbl (Tezuka et al., 1996) , a known negative regulator of BCR-mediated signaling. In addition to playing a role in the inhibition of BCR-mediated signaling events, Lyn has also been shown to play a key role in the inhibition of other receptor-mediated pathways. For example, studies have shown that in Lyn À/À B cells stimulated with CD40, approximately 10-fold less IL-4 was needed to promote immunoglobulin class switching (Janas et al., 1999) . In addition, Lyn also phosphorylates Dok (Yamanashi et al., 2000) following BCR aggregation in a Lyndependent manner and Dok may then target SHIP (5 0 inositol-phosphatase) effector function to negatively regulate BCR signaling.
B-lymphocyte development
In addition to modulating B-cell immune responses by both positive and negative regulation of BCR-mediated signaling events, the SFKs have been shown to play key roles in B-lymphocyte maturation and development. Studies have shown that while B-cell development in the bone marrow progresses normally in Lyn À/À mice, defects are observed in the periphery. These include a lack of mature B cells (Chan et al., 1997) and an increase in the number of B-1 B cells in the peritoneum (Whyburn et al., 2003) . In addition, these mice have substantial splenomegaly that is believed to be caused by infiltrating myeloid cells, neutrophils and plasma cells (Chan et al., 1997; Whyburn et al., 2003) . Similar blocks in development have been observed when crossing Lyn À/À animals onto B-cell transgenic models such as 3-83 Tgs (Meade et al., 2002) . Interestingly, the few mature B cells that do develop in the periphery of nontransgenic Lyn
animals have a lowered threshold for BCR signaling and these mice develop autoantibodies and glomerulonephritis. Whether these autoantibodies develop from the disregulation of the few developing B-2 cells or from the increased numbers of B-1 cells is unknown. One interesting hypothesis to explain the observed autoimmunity in Lyn À/À mice was proposed by Cornall et al. (1998 Cornall et al. ( , 1999 . In these studies, the authors examined the role of lyn in the development and biology of mice that express HEL (hen egg-white lysozyme) as a self-antigen. They suggest that although negative selection in the bone marrow is intact or slightly enhanced, mice lacking Lyn still secrete autoantibody. This may result from the possible failure to delete autoreactive B cells that bind antigen at an affinity below that required for negative selection. Additional work has also shown that loss of CD19 in Lyn À/À mice can prevent autoantibody production . This is presumably due to an increase in the threshold for activation induced by the removal of the positive signaling events mediated by CD19, balanced by the loss of negative effectors regulated by Lyn.
Recent papers have addressed the effect of continuous Lyn activation in vivo using a targeted gain-of-function mutation termed the Lyn up/up mouse (Hibbs et al., 2002) . These studies have provided invaluable insight into the effect of Lyn in B-cell development and add considerably to previous studies. These mice have a substantial reduction in peripheral B-cell numbers and those B cells that do leave the bone marrow express low surface IgM levels compared to wild-type controls. Indeed, B cells purified from the spleen of these animals expressed a number of phenotypic markers normally associated with anergic B cells. These observations made the spontaneous development of autoimmune disease all the more striking. However, additional data showed that B cells from Lyn up/up mice also exhibit enhanced calcium mobilization to BCR aggregation. This is of particular interest because these B cells express constitutively high levels of SHP-1 and CD22 phosphorylation, known negative regulators of BCR signaling. Thus, it would seem that positive signaling events associated with sustained Lyn activation can over-ride negative events also activated by Lyn.
As previously mentioned, Lyn is not the only SFK that plays a role in the development and activation of Blymphocytes and considerable redundancy is believed to exist between these different family members. Thus, while in Lyn À/À animals B-cell development is blocked at the immature/transitional stage, mice lacking Lyn, Fyn and Blk exhibit a earlier block in development at the pre-B-cell stage (Saijo et al., 2003) . This suggests that the multiple SFKs play an important role in the propagation of signals by the pre-BCR and highlights the redundancy that exists between SFKs. In addition, the differential expression of various SFKs during development may play a key role in the outcome of BCR aggregation. In particular, studies by Wechsler and Monroe (1995) have shown that immature B cells in the bone marrow downregulate the expression of Fyn and Fgr. However, these proteins are re-expressed in mature peripheral B cells. BCR aggregation at these two developmental stages causes growth arrest and apoptosis or activation and proliferation, respectively.
Conclusions
The wealth of literature that addresses the function of SFKs have furthered our understanding of how this family of signaling molecules help regulate B-cell development and signaling. The SFK Lyn may be novel in its function as both a positive and negative regulator of BCR signaling. This dual function underscores the importance of balanced signaling by opposing signaling circuits. This equilibrium has important implications in the development of B cells both in the bone marrow and secondary lymphoid organs and is thus crucial in the development of an effective B-cell repertoire. Whether the other SFKs have this similar dual function remains unclear. No doubt future work will address these questions and allow us to fully understand the unique versus redundant roles of each individual SFK in B-cell development and disease.
